Literature DB >> 3896744

Vitamins in psychiatry. Do they have a role?

W M Petrie, T A Ban.   

Abstract

Deficiencies of specific vitamins produce consistent symptoms of psychiatric disorder. Thiamine deficiency, which is common in alcoholism, can produce confusion and psychotic symptoms, in addition to neurological signs. Vitamin B12 and folate deficiency may contribute symptoms of disorientation, depression or psychosis; their measurement is a part of routine dementia work-ups. Pyridoxine deficiency results in seizures, although the effects of exogenously administered pyridoxine are not clearly understood in depression and anxiety - the disorders in which it is most frequently used clinically. The use of vitamins has been most prominent in psychiatry in the treatment of schizophrenia, where large doses of nicotinic acid were initially given alone and later combined with other vitamins and minerals. Several theoretical models were described to support the use of vitamins in schizophrenia. These included: the parallels of schizophrenia to the psychiatric symptoms of pellagra; hypotheses of a defect in adrenaline metabolism; and the accumulation of psychotoxic substances which produce psychotic symptoms. Initially, positive results were reported over 30 years ago, but have not been replicated by thorough investigations. An extensive series of comprehensive placebo-controlled trials failed to show efficacy for any of the vitamin therapies tested. Although clearly less effective than antipsychotic drug treatment, vitamin therapy is not without risks - adverse effects have been reported with nicotinic acid, pyridoxine and vitamin C.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3896744     DOI: 10.2165/00003495-198530010-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  31 in total

1.  The effects of nicotinic acid, nicotinamide, and placebo on the chronic schizophrenic.

Authors:  W R ASHBY; G H COLLINS; M BASSETT
Journal:  J Ment Sci       Date:  1960-10

2.  Nicotinamide in the treatment of schizophrenia.

Authors:  R DENSON
Journal:  Dis Nerv Syst       Date:  1962-03

3.  Schizophrenia; a new approach. II. Result of a year's research.

Authors:  A HOFFER; H OSMOND; J SMYTHIES
Journal:  J Ment Sci       Date:  1954-01

4.  Schizophrenia: a new approach.

Authors:  H OSMOND; J SMYTHIES
Journal:  J Ment Sci       Date:  1952-04

5.  Negative findings with nicotinic acid in the treatment of schizophrenias.

Authors:  T A Ban
Journal:  Int Pharmacopsychiatry       Date:  1974

6.  Reversible dementia and neuropathy associated with folate deficiency 16 years after partial gastrectomy.

Authors:  C Enk; K Hougaard; E Hippe
Journal:  Scand J Haematol       Date:  1980-07

7.  Effect of folic acid and vitamin B12 deficiencies on 5-hydroxyindoleacetic acid in human cerebrospinal fluid.

Authors:  M I Botez; S N Young; J Bachevalier; S Gauthier
Journal:  Ann Neurol       Date:  1982-11       Impact factor: 10.422

8.  The Wernicke-Korsakoff syndrome.

Authors:  J F Feinberg
Journal:  Am Fam Physician       Date:  1980-11       Impact factor: 3.292

9.  Pellagra among chronic alcoholics: clinical and pathological study of 20 necropsy cases.

Authors:  N Ishii; Y Nishihara
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-03       Impact factor: 10.154

10.  Thiamine, riboflavin and pyridoxine deficiency in psychiatric in-patients.

Authors:  M W Carney; A Ravindran; M G Rinsler; D G Williams
Journal:  Br J Psychiatry       Date:  1982-09       Impact factor: 9.319

View more
  2 in total

Review 1.  Vitamin supplementation in the treatment of schizophrenia.

Authors:  Hannah E Brown; Joshua L Roffman
Journal:  CNS Drugs       Date:  2014-07       Impact factor: 5.749

2.  Methylation patterns in whole blood correlate with symptoms in schizophrenia patients.

Authors:  Jingyu Liu; Jiayu Chen; Stefan Ehrlich; Esther Walton; Tonya White; Nora Perrone-Bizzozero; Juan Bustillo; Jessica A Turner; Vince D Calhoun
Journal:  Schizophr Bull       Date:  2013-06-03       Impact factor: 9.306

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.